Cybin Inc. (NASDAQ:HELP) Stock Has Average Target Price of $46.33

Posted by on Oct 10th, 2026

Shares of Cybin Inc. (NASDAQ:HELP – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $46.33.

Several equities analysts recently commented on the company. Barclays assumed coverage on Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 target price for the company. Wall Street Zen cut Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. TD Cowen upped their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Wells Fargo & Company began coverage on shares of Cybin in a research report on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price on the stock.

Check Out Our Latest Report on Cybin

Insider Activity at Cybin

In other news, insider Eric H. L. So bought 100,000 shares of Cybin stock in a transaction that occurred on Tuesday, September 8th. The shares were purchased at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the acquisition, the insider owned 4,465,014 shares of the company’s stock, valued at $55,321,523.46. The trade was a 2.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Greg Cavers bought 3,000 shares of Cybin stock in a transaction that occurred on Tuesday, September 29th. The stock was purchased at an average price of $12.91 per share, for a total transaction of $38,730.00. Following the acquisition, the chief financial officer directly owned 3,000 shares of the company’s stock, valued at $38,730. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 688,000 shares of company stock valued at $8,422,830 over the last quarter. 15.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cybin

A number of large investors have recently modified their holdings of the company. Pale Fire Capital SE purchased a new stake in shares of Cybin during the 2nd quarter worth about $1,015,000. Farther Finance Advisors LLC increased its position in Cybin by 927.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock worth $280,000 after purchasing an additional 20,597 shares in the last quarter. Finally, AXQ Capital LP purchased a new position in Cybin in the second quarter valued at approximately $75,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Stock Performance

Shares of NASDAQ HELP opened at $11.80 on Friday. The firm has a market cap of $939.16 million, a P/E ratio of -3.91 and a beta of 0.53. Cybin has a 1 year low of $3.76 and a 1 year high of $15.15. The firm’s 50 day moving average price is $12.07 and its 200 day moving average price is $7.78.

Cybin (NASDAQ:HELP – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). As a group, equities analysts predict that Cybin will post -2.95 EPS for the current year.

Cybin Company Profile

(Get Free Report)

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder.

Featured Stories

Analyst Recommendations for Cybin (NASDAQ:HELP)

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.